Showing 5811-5820 of 8792 results for "".
- Pfizer-AGN Deal Offhttps://practicaldermatology.com/news/all-eyes-on-pfizer-agn-deal-is-it-doa/2458617/UPDATE: Allergan and Pfizer have mutually agreed to end their merger agreement, according to a statement from Allergan. Pfizer has agreed to pay Allergan $150 million in reimbursement for expenses associated with the transaction. Dublin-based Allergan reiterates in the statement its growth opport
- Rosacea Awareness Month Highlights Potential Increased Health Riskshttps://practicaldermatology.com/news/rosacea-awareness-month-highlights-potential-increased-health-risks/2458624/New studies are now revealing potential associations between rosacea and increased risks of cardiovascular disease, gastrointestinal disease, certain types of cancer and many other systemic illnesses. The National Rosacea Society (NRS) has designated April as Rosacea Awareness Month to alert the
- Alma Lasers to Launch Accent Prime for Body Contouring and Skin Tightening Treatmentshttps://practicaldermatology.com/news/alma-lasers-to-launch-accent-prime-for-body-contouring-and-skin-tightening-treatments/2458626/Alma Lasers launched Accent Prime, the latest addition to the company's family of body contouring products. This new platform combines the most advanced innovations in ultrasound and Unipolar radio frequency technologies to deliver fast, effective, highly customized treatments with long lasti
- Victoria Kennedy receives ASLMS' First Leadership, Mentorship & Public Advocacy for Women in Medical Science Awardhttps://practicaldermatology.com/news/victoria-kennedy-receives-aslms-first-leadership-mentorship-public-advocacy-for-women-in-medical-science-award/2458628/Victoria Reggie Kennedy will receive the first Leadership, Mentorship & Public Advocacy for Women in Medical Science Award at the annual meeting of the American Society for Laser Medicine and Surgery (ASLMS). The award will be presented at th
- North America's Scar Treatment Poised for Growth Spurt by 2022https://practicaldermatology.com/news/north-america-scar-treatment-market-set-to-grow-by-2022/2458629/Scar treatment will be a hot growth area in coming years, according to a new report by Persistence Market Research. The report cites a rising incidence of burn and trauma cases and an increasing preval
- More Than 1,000 Patients Join Corrona Psoriasis Registryhttps://practicaldermatology.com/news/more-than-1000-patients-join-corrona-psoriasis-registry/2458631/The Corrona Psoriasis Registry, a joint collaboration between the National Psoriasis Foundation (NPF) and Corrona, LLC, now includes more than 1,000 patients from 100 sites. Dermatologists assess registry pa
- FDA Clears Venus Versa for 20-Plus Common Clinical Indicationshttps://practicaldermatology.com/news/fda-clears-venus-versatm-for-20-plus-common-clinical-indications/2458632/The U.S. Food and Drug Administration cleared Venus Concept’s Venus Versa™ system for skin rejuvenation, hair removal, facial wrinkles and rhytides, skin resurfacing, pigmented and vascular lesions, and acne vulgaris.
- Take That, Melanoma! New Patch Delivers Anti-PD-1 Antibodies Directly to Skin Cancerhttps://practicaldermatology.com/news/take-that-melanoma-new-patch-delivers-anti-pd-1-antibodies-directly-to-skin-cancer/2458633/A new patch embedded with microneedles may deliver anti-PD-1 antibodies directly to the site of melanoma, according to a study in Nano Letters. In animal studies, the technique more effectively targeted
- Profounda Launches Impavido for Visceral, Mucosal and Cutaneous Leishmaniasishttps://practicaldermatology.com/news/profounda-launches-impavido-for-visceral-mucosal-and-cutaneous-leishmaniasis/2458636/Profounda, Inc. launched Impavido (miltefosine) in the United States. Impavido is the first oral treatment for visceral, mucosal and cutaneous leishmaniasis approved by the FDA and the first Rx product launched in the US by Profounda. Although skin sores of cutaneous leishmaniasis (CL) us
- FDA Greenlights Taltz for Psoriasishttps://practicaldermatology.com/news/fda-greenlights-taltz-for-psoriasis/2458635/The U.S. Food and Drug Administration approved the IL-17A blocker Taltz (ixekizumab) for adults with moderate-to-severe plaque psoriasis. Taltz is marketed by Indianapolis, Indiana-based Eli Lilly and Company. Given via